Prostate Cancer - Results from #1460

Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer. February 6, 2024

The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer. February 6, 2024

Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer. February 5, 2024

Validation of a Quality Metric Score to Assess the Placement of Hydrogel Rectal Spacer in Patients Treated With Prostate Stereotactic Radiation Therapy. February 5, 2024

Current evidence on local therapy in oligometastatic prostate cancer. February 5, 2024

Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. February 5, 2024

Converting between the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC) urinary subscales: modeling and external validation. February 5, 2024

Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer. February 2, 2024

Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database. February 2, 2024

Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study. February 2, 2024

HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol. February 2, 2024

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer. February 2, 2024

Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study. February 2, 2024

Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib. February 2, 2024

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). February 1, 2024

Impact of Prostate Size on the Functional and Oncological Outcomes of Robot-assisted Radical Prostatectomy. February 1, 2024

The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer. February 1, 2024

Robustness of magnetic resonance imaging and positron emission tomography radiomic features in prostate cancer: Impact on recurrence prediction after radiation therapy. February 1, 2024

Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation. February 1, 2024

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium January 31, 2024

Page 74 of 1438